A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Capsules
Diarrhea
Dose-Response Relationship, Drug
Drug Administration Schedule
Fatigue
Female
Humans
Middle Aged
Nausea
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Phthalazines
Piperazines
Quinazolines
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Receptors, Vascular Endothelial Growth Factor
Tablets
Treatment Outcome

authors with profiles

Michael Birrer